Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-04-2020 | Editorial

¹⁶⁶Ho microsphere scout dose for more accurate radioembolization treatment planning

Authors: C Chiesa, M Maccauro

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2020

Excerpt

Radioembolization is nowadays dominated by ^99mTc MAA for pretreatment study of biodistribution and dosimetry, and by ⁹⁰Y microspheres for therapy Physical properties of such radionuclide are: 64 h half-life, beta emission maximal energy 2280 keV, beta abundance 99.9%, no gamma, and 32 positron emissions per million of transformations. A new kind of medical device available for therapy recently became commercially available also for planning: polylactic acid (PLLA) microspheres labeled with ¹⁶⁶Ho. Such radionuclide has a 26.8 h half-life, dual beta emission with maximal energy of 1770 keV (49%)–1850 keV (50%) and, new aspect, it is paramagnetic and it emits gamma photons at 81 keV, with low abundance (6.7%). Gamma photons allow SPECT/CT imaging and dosimetry (some days after therapy to avoid gammacamera saturation) [1], while paramagnetism gives the additional possibility of post-therapy MRI evaluation. Publications about the use of ¹⁶⁶Ho in therapy are available [2, 3], but this application is not under discussion here. …

Elschot M, Nijsen JF, Dam AJ, de Jong HW. Quantitative evaluation of scintillation camera imaging characteristics of isotopes used in liver radioembolization. PLoS One. 2011;6(11):e26174.CrossRefPubMedPubMedCentral

Smits MLJ, Nijsen JFW, van den Bosch MAAJ, Lam MGEH, Vente MAD, Mali WPTM, van het Schip AD, BA Zonnenberg. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. Lancet Oncol. 2012;13:1025-1034.CrossRefPubMed

Smits MLJ, Elschot M, van den Bosch MAAJ, van de Maat GH, van het Schip AD, Zonnenberg BA, et al. In vivo dosimetry based on SPECT and MR imaging of 166Ho-microspheres for treatment of liver malignancies. J Nucl Med. 2013;54:1–8.CrossRef

Smits MLJ, Dassen MG, Prince JF, Braat AJAT, Beijst C, Bruijnen RCG, et al. The superior predictive value of 166Ho-scout compared with ^99mTc-macroaggregated albumin prior to 166Ho-microspheres radioembolization in patients with liver metastases. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-019-04460-y.

Prince JF, van Rooij R, Bol GH, de Jong HWAM, van den Bosch MAAJ, Lam MGEH. Safety of a scout dose preceding hepatic radioembolization with 166Ho microspheres. J Nucl Med. 2015;56:817–23.CrossRefPubMed

Knesaurek K, Machac J, Muzinic M, DaCosta M, Zhang Z, Heiba S. Quantitative comparison of yttrium-90 (⁹⁰Y)-microspheres and technetium-99m (^99mTc)-macroaggregated albumin SPECT images for planning ⁹⁰Y therapy of liver cancer. Technol Cancer Res Treat. 2010;9:253–62.CrossRefPubMed

Jiang M, Fishman A, Nowakowski FS, Heiba S, Zhang Z, Knesaurek K, et al. Segmental perfusion differences on paired Tc-99m macroaggregated albumin (MAA) hepatic perfusion imaging and yttrium-90 Y-90 bremstrahlung imaging studies in SIR-spere radioembolization: associations with angiography. J Nucl Med Radiat Ther. 2012;3:1.CrossRef

Wondergem M, Smits ML, Elschot M, de Jong HW, Verkooijen HM, van den Bosch MA, et al. 99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of ⁹⁰Y resin microspheres in hepatic radioembolization. J Nucl Med. 2013;54:1294–301. https://doi.org/10.2967/jnumed.112.117614.CrossRefPubMed

Elschot M, Nijsen JFW, Lam MGEH, et al. 99mTc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with 166Homicrospheres. Eur J Nucl Med Mol Imaging. 2014;41:1965–75.CrossRefPubMed

10.

Hunt AP, Frier M, Johnson RA, Berezenko S. A.C. Perkins Preparation of Tc-99mmacroaggregated albumin from recombinant human albumin for lung perfusion imaging. Eur J Pharm Biopharm. 2006;62:26–31.CrossRefPubMed

11.

Altman DG, Bland JM. Measurement in medicine: the analysis of method comparison studies. Statistician. 1983;32:307–17 https://doi.org/10.2307/2987937.CrossRef

12.

Kopp-Schneider A, Hielscher T. How to evaluate agreement between quantitative measurements. Radiother Oncol. 2019 Sep 25. pii: S0167-8140(19)33077-33074. doi: https://doi.org/10.1016/j.radonc.2019.09.004. [Epub ahead of print]CrossRefPubMed

13.

Gnesin S, Canetti L, Adib S, Cherbuin N, Silva Monteiro M, Bize P, et al. Boubaker. A partition model-based 99mTc-MAA SPECT/CT predictive dosimetry compared with ^90Y TOF PET/CT posttreatment dosimetry in radioembolization of hepatocellular carcinoma: a quantitative agreement comparison. J Nucl Med. 2016 Nov;57(11):1672–8.CrossRefPubMed

14.

Jadoul A, Bernard C, Lovinfosse P, Gérard L, Lilet H, Cornet O, et al. Comparative dosimetry between 99mTc-MAA SPECT/CT and ^90Y PET/CT in primary and metastatic liver tumors. Eur J Nucl Med Mol Imaging. 2019 Aug;6. https://doi.org/10.1007/s00259-019-04465-7 [Epub ahead of print].

15.

Kafrouni M, Allimant C, Fourcade M, Vauclin S, Guiu B, Mariano-Goulart D, et al. Analysis of differences between 99mTc-MAA SPECT- and ^90Y-microsphere PET-based dosimetry for hepatocellular carcinoma selective internal radiation therapy. EJNMMI Res. 2019;9:62.CrossRefPubMedPubMedCentral

16.

Richetta E, Pasquino M, Poli M, Cutaia C, Valero C, Tabone M, et al. PET-CT post therapy dosimetry in radioembolization with resin ^90Y microspheres: comparison with pre-treatment SPECT-CT ^99mTc-MAA results. Phys Med. 2019;64:16–23. https://doi.org/10.1016/j.ejmp.2019.05.025.CrossRefPubMed

17.

Haste P, Tann M, Persohn S, LaRoche T, Aaron V, Mauxion T, et al. Correlation of technetium-99m macroaggregated albumin and yttrium-90 glass microsphere biodistribution in hepatocellular carcinoma: a retrospective review of pretreatment single photon emission CT and posttreatment positron emission tomography/CT. J Vasc Interv Radiol. 2017;28:722–30.CrossRefPubMed

18.

Pacilio M, Ferrari M, Chiesa C, Lorenzon L, Mira M, Botta F, et al. Impact of SPECT corrections on 3Ddosimetry for liver transarterial radioembolization using the patient relative calibration methodology. Med Phys. 2016 Jul;43(7):4053.CrossRefPubMed

19.

Botta F, Ferrari M, Chiesa C, Vitali S, Guerriero F, Nile MC, et al. Impact of missing attenuation and scatter corrections on ^99m Tc-MAA SPECT 3D dosimetry for liver radioembolization using the patient relative calibration methodology: a retrospective investigation on clinical images. Med Phys. 2018 Apr;45(4):1684–98. https://doi.org/10.1002/mp.12774.CrossRefPubMed

20.

Lau WY, Kennedy AS, Kim YH, Lai HK, Lee RC, Leung TW, et al. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys. 2012;82:401–7. https://doi.org/10.1016/j.ijrobp.2010.08.015.CrossRefPubMed

21.

Strigari L, Sciuto R, Rea S, Carpanese L, Pizzi G, Soriani A, et al. Efficacy and toxicity related to treatment of hepatocellular carcinoma with ^90Y SIR spheres: radiobiologic considerations. J Nucl Med. 2010;51:1377–85.CrossRefPubMed

22.

Chiesa C, Mira M, Maccauro M, Spreafico C, Romito R, Morosi C, et al. Radioembolization of hepatocarcinoma with 90-Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology. Eur J Nucl Med Mol Im. 2015;42:1718–38.CrossRef

23.

Salem R, Padia SA, Lam M, Bell J, Chiesa C, Fowers K, et al. Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging. 2019;46(8):1695–704.CrossRefPubMed

24.

Garin E, Lenoir L, Edeline J, Laffont S, Mesbah H, Porée P, et al. Boosted selective internal radiation therapy with ^90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging. 2013;40:1057–68.CrossRefPubMedPubMedCentral

25.

Garin E, Lenoir L, Rolland Y, Edeline J, Mesbah H, Laffont S. Dosimetry based on ^99mTcmacroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with ^90Y-loaded glass microspheres: preliminary results. J Nucl Med. 2012;53:255–63.CrossRefPubMed

26.

ICRU report 24 determination of absorbed dose in a patient irradiated by beams of X or gamma rays in radiotherapy. Journal of the International Commission on Radiation Units and Measurements. https://doi.org/10.1093/jicru/os13.1.Report24.

27.

Garin E, Rolland Y, Pracht M, Le Sourd S, Laffont S, Mesbah H, et al. High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microsphere radioembolization. Liver Int. 2017;37:101–10.CrossRefPubMed

28.

Kokabi N, Galt JR, Xing M, Camacho JC, Barron BJ, Schuster DM, et al. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study. J Vasc Interv Radiol. 2014;25:277–87.CrossRefPubMed

29.

Cremonesi M, Chiesa C, Strigari L, Ferrari M, Botta F, Guerriero F, et al. Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective. Front Oncol. 2014;4:210. https://doi.org/10.3389/fonc.2014.00210 eCollection 2014.CrossRefPubMedPubMedCentral

30.

Garin E, Rolland Y, Laffont S, Edeline J. Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres. Eur J Nucl Med Mol Imaging. 2016;43(3):559–75.CrossRefPubMed

31.

Prince F, Smits MLJ, Krijger GC, Zonnenberg BA, van den Bosch MAAJ, Nijsen JFW, et al. Radiation emission from patients treated with holmium-166 radioembolization. J Vasc Interv Radiol. 2014;25:1956–1963ù.CrossRefPubMed

32.

Australian Radiation Protection and Nuclear Safety Agency - Radiation Protection Series n. 4 - Recommendations for the discharge of patients undergoing treatment with radioactive substances 2002

33.

Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;12(18(12)):1624–36.CrossRef

34.

Van Der Gucht A, Jreige M, Denys A, Blanc-Durand P, Boubaker A, Pomoni A, et al. Resin versus glass microspheres for ^90Y transarterial radioembolization: comparing survival in unresectable hepatocellular carcinoma using pretreatment partition model dosimetry. J Nucl Med. 2017 Aug;58(8):1334–40.CrossRef

Title: 166Ho microsphere scout dose for more accurate radioembolization treatment planning
Authors: C Chiesa
M Maccauro
Publication date: 01-04-2020
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2020
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-019-04617-9

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

¹⁶⁶Ho microsphere scout dose for more accurate radioembolization treatment planning

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2020

Hypoxia-induced modulation of glucose transporter expression impacts 18F-fluorodeoxyglucose PET-CT imaging in hepatocellular carcinoma

Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE

Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety

Comparative dosimetry between 99mTc-MAA SPECT/CT and 90Y PET/CT in primary and metastatic liver tumors

The radiosensitizer Onalespib increases complete remission in 177Lu-DOTATATE-treated mice bearing neuroendocrine tumor xenografts

A case of abdominal wall percutaneous endoscopic gastrostomy site metastatic disease from primary oropharyngeal squamous cell carcinoma